Nurix reported a quarterly loss of $0.79 per share versus the Zacks consensus loss of $0.76, missing estimates by $0.03 (≈4%). The loss widened from $0.67 a year ago (≈18% larger), indicating modestly weaker profitability than expected and a negative near-term earnings surprise for the biotech name.
Nurix reported a quarterly loss of $0.79 per share versus the Zacks consensus loss of $0.76, missing estimates by $0.03 (≈4%). The loss widened from $0.67 a year ago (≈18% larger), indicating modestly weaker profitability than expected and a negative near-term earnings surprise for the biotech name.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
